|
1.
|
|
13 p, 471.4 KB |
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial
/
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nahi, Hareth (Department of Medicine. Karolinska University) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Bahlis, Nizar J. (University of Calgary) ;
Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ;
Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ;
Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ;
Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ;
Plesner, Torben (University of Southern Denmark) ;
Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ;
Ben Yehuda, Dina (Hematology Department. Hebrew University) ;
Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Goldschmidt, Hartmut (Heidelberg University Hospital (Alemanya)) ;
Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ;
Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ;
Qin, Xiang (Janssen Research & Development (Xina)) ;
Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ;
Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ;
Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 -  10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599
|
|
|
2.
|
|
11 p, 396.3 KB |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics
/
Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ;
Schjesvold, Fredrik (University of Oslo) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf) ;
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Anderson, Larry D. (University of Texas Southwestern Medical Center) ;
White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Sonneveld, Pieter (Erasmus MC Cancer Institute) ;
Engelhardt, Monika (Universitätsklinikum Freiburg) ;
Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Corso, Alessandro (Hospital of Legnano) ;
Dürig, Jan (University Hospital Essen (Alemanya)) ;
Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ;
Salomo, Morten (Copenhagen University Hospital) ;
Beksac, Meral (Ankara University) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ;
Liberati, Anna Marina (University of Perugia) ;
Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ;
Robak, Pawel (Medical University of Lodz) ;
Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ;
Yagci, Munci (Gazi University Medical Faculty) ;
Vural, Filiz (Ege University) ;
Kanate, Abraham (West Virginia University) ;
Jiang, Ruiyun (Bristol Myers Squibb) ;
Grote, Lara (Bristol Myers Squibb) ;
Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ;
Dimopoulos, Meletios (National and Kapodistrian University of Athens)
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. [...]
2022 - 10.1111/ejh.13706
European Journal of Haematology, Vol. 108 Núm. 1 (january 2022) , p. 73-83
|
|
|
3.
|
|
3 p, 444.0 KB |
Prevention of veno-occlusive disease/sinusoidal obstruction syndrome : a never-ending story and no easy answer
/
Corbacioglu, Selim (University of Regensburg) ;
Grupp, S.A. (The Children's Hospital of Philadelphia) ;
Richardson, Paul G.. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Duarte, R. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Pagliuca, A. (King's College Hospital and Anthony Nolan Research Institute) ;
Ruutu, T. (Helsinki University Hospital) ;
Mahadeo, K. (Duke University Children's Hospital) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
2023 - 10.1038/s41409-023-02007-2
Bone marrow transplantation, Vol. 58 Núm. 8 (august 2023) , p. 839-841
|
|
|
4.
|
|
10 p, 306.4 KB |
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study
/
Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ;
Leleu, Xavier (CHU de Poitiers) ;
Touzeau, Cyrille (Université d'Angers) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paner, Agne (Rush University Medical Center) ;
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ;
Cavo, Michele (Bologna University School of Medicine) ;
Maisel, Christopher (Baylor Scott & White Charles A) ;
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ;
Laubach, Jacob (Harvard Medical School) ;
Nadeem, Omar (Harvard Medical School) ;
Sandberg, Anna (Oncopeptides AB (Suècia)) ;
Orre, Marie (Oncopeptides AB (Suècia)) ;
Torrång, Anna (SDS Life Science (Suècia)) ;
Bakker, Nicolaas A (Oncopeptides AB) ;
Richardson, Paul G.. (Harvard Medical School) ;
Universitat Autònoma de Barcelona
Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. [...]
2022 - 10.1111/bjh.17887
British Journal of Haematology, Vol. 196 Núm. 3 (february 2022) , p. 639-648
|
|
|
5.
|
|
13 p, 449.0 KB |
Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma
/
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Larocca, Alessandra (Università di Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza) ;
Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona) ;
Cavo, Michele (Seràgnoli Institute of Hematology. Bologna University School of Medicine) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Leleu, Xavier (CHU de Poitiers) ;
Nadeem, Omar (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Hiemenz, John W. (Division of Hematology-Oncology. Department of Medicine. University of Florida) ;
Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ;
Touzeau, Cyrille (Université de Nantes) ;
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ;
Paner, Agne (Rush University Medical Center) ;
Maisel, Christopher (Baylor Scott & White Charles A. Sammons Cancer Center) ;
Mazumder, Amitabha (Oncology Institute of Hope and Innovation) ;
Raptis, Anastasios (Universityof Pittsburgh School of Medicine) ;
Moreb, Jan S. (Novant Health Hematology. Novant Health Forsyth Medical Center) ;
Anderson, Kenneth C. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Laubach, Jacob P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Thuresson, Sara (Oncopeptides AB) ;
Thuresson, Marcus (Oncopeptides AB) ;
Byrne, Catriona (Oncopeptides AB) ;
Harmenberg, Johan (Oncopeptides AB) ;
Bakker, Nicolaas A. (Oncopeptides AB) ;
Mateos, M. V (Hospital Clínico Universitario (Salamanca))
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. [...]
2021 - 10.1200/JCO.20.02259
Journal of Clinical Oncology, Vol. 39 Núm. 7 (january 2021) , p. 757-767
|
|
|
6.
|
|
11 p, 1.3 MB |
Melflufen for relapsed and refractory multiple myeloma
/
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Larocca, Alessandra (Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino. University of Torino) ;
Leleu, Xavier (Department of Hematology. CHU De Poitiers) ;
Hájek, R (Department of Hemato-Oncology. University of Ostrava and Faculty of Medicine. University of Ostrava) ;
Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ;
Rodríguez-Otero, P. (Clínica Universidad de Navarra) ;
Paner, A. (Division of Hematology. Oncology and Stem Cell Transplant. Rush University Medical Center) ;
Schjesvold, F. H. (Oslo Myeloma Center. Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies. University of Oslo) ;
Gullbo, J. (Department of Medical Sciences. Division of Clinical Pharmacology. Uppsala University) ;
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Jerome Lipper Multiple Myeloma Center) ;
Universitat Autònoma de Barcelona
Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. [...]
2020 - 10.1080/13543784.2020.1808884
Expert Opinion on Investigational Drugs, Vol. 29 Núm. 10 (february 2020) , p. 1069-1078
|
|
|
7.
|
|
11 p, 572.5 KB |
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group
/
Mohty, Mohamad (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Malard, F. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Abecasis, Manuel (Instituto Portugues de Oncologia) ;
Aerts, E. (University Hospital Zurich (Suïssa)) ;
Alaskar, A. S. (Department of Oncology. King Abdulaziz Medical City. King Abdullah International Medical Research Center. King Saud Bin Abdulaziz University for Health Sciences. Ministry of National Guard Health Affairs) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre) ;
Arat, Mutlu (HSCT Unit. Sisli Florence Nightingale Hospital) ;
Bader, Peter (Division for Stem Cell Transplantation and Immunology. Department for Children and Adolescents. University Hospital. Goethe University) ;
Baron, Frederic (CHU and University of Liege) ;
Basak, G. (Medical University of Warsaw) ;
Bazarbachi, A. (American University of Beirut. Department of Internal Medicine) ;
Blaise, Didier (Transplant and Cellular Immunotherapy Program. Department of Hematology. Aix-Marseille Univ. Inserm. CNRS. Institut Paoli-Calmettes. CRCM) ;
Ciceri, Fabio (Hematology and Bone Marrow Transplantation Unit. IRCCS Ospedale San Raffaele. University Vita-Salute) ;
Corbacioglu, Selim (Department of Pediatric Hematology. Oncology and Stem Cell Transplantation. University of Regensburg) ;
Dalle, J. H. (Department of Hematology and Immunology. Hospital Robert Debre. Paris 7-Paris Diderot University) ;
Dignan, F. (Department of Clinical Haematology. Central Manchester Foundation Trust) ;
Fukuda, T. (HSCT Division. National Cancer Center Hospital) ;
Huynh, A. (Institut Universitaire du Cancer Toulouse-Oncopole) ;
Kuball, J. (Department of Haematology. University Medical Centre) ;
Lachance, S. (Department of Hematology and Stem Cell Transplant Program. Hôpital Maisonneuve-Rosemont. University of Montreal) ;
Lazarus, H. (Case Western Reserve University) ;
Masszi, T. (St László Hospital (Hongria)) ;
Michallet, M. (Hematology Department. Groupement Hospitalier Sud. Hospices Civils de Lyon. Université Claude Bernard Lyon EST) ;
Nagler, Arnon (Hematology and Bone Marrow Transplantation. Chaim Sheba Medical Center) ;
NiChonghaile, M. (Trinity College Dublin) ;
Okamoto, S. (Division of Hematology. Department of Medicine. Keio University School of Medicine) ;
Pagliuca, A. (King's College Hospital NHS Foundation Trust) ;
Peters, C. (Department of Pediatrics. St. Anna Kinderspital) ;
Petersen, F. B. (LDS Hospital) ;
Richardson, Paul G.. (Division of Hematology. Mayo Clinic) ;
Ruutu, T. (Helsinki University Hospital (Finlàndia)) ;
Saber, Wael (Center for International Blood and Marrow Transplant Research. Medical College of Wisconsin) ;
Savani, B. N. (Hematology and Stem Cell Transplantation Section. Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center and Veterans Affairs Medical Center) ;
Soiffer, R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Division of Hematologic Malignancies) ;
Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum UMK) ;
Wallhult, E. (Sahlgrenska University Hospital (Suècia)) ;
Yakoub-Agha, Ibrahim (CHU de Lille. LIRIC INSERM U995. Université de Lille2) ;
Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
2020 - 10.1038/s41409-019-0705-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 485-495
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
